On August 2, 2023 Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the "Company") reported an investment of US $2.0 million for 2 million shares at the price of $1.00 per share with 500,000 warrants priced at $2.00 (Press release, Nymox, AUG 2, 2023, View Source [SID1234633652]). The investment comes from James Robinson, a long-term shareholder of Nymox and a distinguished member of the Board of Directors of the Company. The funds will be used for general corporate purposes. The investment will close in the upcoming days after the customary formalities are completed.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!